Natural history of cancer-associated splanchnic vein thrombosis
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.01.019 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Hanqing Shang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Venous Thrombosis, Splanchnic Circulation, Neoplasms, Anticoagulants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
BACKGROUND: There is uncertainty in the management of cancer-associated isolated splanchnic vein thrombosis (SpVT). OBJECTIVES: To describe the natural history of SpVT by cancer type and thrombus composition and to review anticoagulation (AC) practices and associated rates of usual-site venous thromboembolism (VTE), major and clinically relevant nonmajor bleeding (MB/CRNMB), recanalization/progression, and mortality. METHODS: We performed a retrospective cohort study in patients with SpVT at 2 cancer care centers in Houston, Texas. We estimated the incidence of usual-site VTE and MB/CRNMB at 6 months using competing risk methods and examined venous patency in a subset of patients with repeat imaging. We assessed associations with mortality using Cox regression. RESULTS: Among 15 342 patients with an incident cancer diagnosis from 2011 to 2020, we identified 298 with isolated SpVT. Patients with hepatocellular carcinoma (HCC) and SpVT (n = 146) had the highest disease prevalence (20%), lowest rate of AC treatment (2%), and similar rate of usual-site VTE (4.2%) vs those without SpVT (5.2%) at 6 months, though tumor thrombus vs bland was associated with worse overall survival. In patients with non-HCC bland SpVT (n = 114), AC (n = 37) was more common in those with non-upper gastrointestinal cancers and fewer comorbidities. AC was associated with more recanalization (44% vs 15%, P = .041) but no differences in usual-site VTE, MB/CRNMB, or mortality at 6 months. CONCLUSION: Cancer-associated isolated SpVT is a common but heterogeneous thrombotic disease that is treated differently from usual-site VTE. Tumor thrombus is a negative prognostic factor. Initiation of AC in bland thrombi requires judicious consideration of thrombotic and bleeding risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA.
- Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.
- Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
- Harris Health System, Houston, Texas, USA.
- Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: ang.li2@bcm.edu.
Förderung
- NHLBI NIH HHS
- NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- NHLBI
Zitieren
APA
Shang, H., Jiang, J. Y., Guffey, D., Novoa, F., Bandyo, R., Ma, S., & Li, A. (2024). Natural history of cancer-associated splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.01.019
Vancouver
Shang H, Jiang JY, Guffey D, Novoa F, Bandyo R, Ma S, et al. Natural history of cancer-associated splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.01.019
BibTeX
@article{Shang2024,
author = {Shang, Hanqing and Jiang, Jun Y and Guffey, Danielle and Novoa, Francisco and Bandyo, Raka and Ma, Shengling and Li, Ang},
title = {Natural history of cancer-associated splanchnic vein thrombosis},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.01.019}
}
EUVIMED